French pharmaceutical company Servia as well as generic producers including Israel’s Teva received formal objections from the European Commission concerning alleged entry delay of the generic form of cardiovascular drug perindopril. By both buying up rare technology needed to create the drug and settling out of court with would-be generic producers, the Commission believes Servier abused its dominant market position by restricting competitive business. Similar pay-for-delay practices were denounced only a few days ago in the Commission’s objections issued to pharmaceutical powerhouse Lundbeck.
Featured News
Antitrust Suit Against Apple, Visa, and Mastercard Dismissed by Federal Judge
Jul 10, 2025 by
CPI
Google’s Antitrust Woes Mount as Turkey Levels Another Fine
Jul 10, 2025 by
CPI
Australian Competition Commission Approves Lactalis Bid for Fonterra Brands
Jul 10, 2025 by
CPI
Trump Administration Sues California Over Egg Laws, Citing Nationwide Price Hikes
Jul 10, 2025 by
CPI
Blackstone Raises Warehouse REIT Bid to £489M, Topping Rival
Jul 10, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – eDiscovery & Antitrust
Jun 30, 2025 by
CPI
Off-Channel and Ephemeral Messaging in Antitrust Investigations: Legal Risks, Regulatory Focus, and Ediscovery Challenges
Jun 30, 2025 by
Daniel Rupprecht & Tristan Jenkinson
Encrypted Messaging in the Crosshairs: Compliance, Legal Risks, and Global Perspectives
Jun 30, 2025 by
Corey Bieber & Guillermo Christensen
Ephemeral and Encrypted Messaging: DOJ Expectations, Compliance Risks, and Best Practices
Jun 30, 2025 by
Megan Gerking, Joe Folio, Haydn Forrest & Adrienne Irmer
Antitrust Litigation in the Age of GenAI
Jun 30, 2025 by
Robin Perkins & Tom Gricks